Related Experiment Video

Updated: Apr 29, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K

Analysis of clinical trials and off-label drug use in hospitalized pediatric patients

Tamara Roldán1, Elena Villamañán1, Margarita Ruano1

  • 1Servicio de Farmacia, Hospital Universitario La Paz, Madrid, España.

Archivos Argentinos De Pediatria
|May 28, 2014
PubMed

Insights

Pediatric clinical trials (PCTs) increased, but most were not randomized. Off-label drug use (OLDU) in children remained constant despite more research.

Area of Science:

  • Pediatric pharmacology
  • Clinical trial design
  • Drug utilization studies

Background:

  • Lack of pediatric clinical trials (PCTs) contributes to off-label drug use (OLDU) in children.
  • Pediatric drug safety and efficacy are critical public health concerns.
  • Understanding trends in PCTs and OLDU is essential for improving pediatric healthcare.

Purpose of the Study:

  • To analyze the number and design of pediatric clinical trials (PCTs).
  • To assess the prevalence and trends of off-label drug use (OLDU) in hospitalized children.
  • To evaluate the relationship between PCTs and OLDU in a pediatric setting.

Main Methods:

  • Retrospective observational study of PCTs and OLDU from 2007-2012.
  • Data collected from a 252-bed children's hospital.
  • Analysis of drug prescriptions, active ingredients, and trial designs.

Main Results:

  • Eighty-seven PCTs and 1049 drugs were evaluated; 26% of drugs were used off-label.
  • PCTs increased from 2008-2011, with a majority being non-randomized and uncontrolled.
  • Off-label drug use (OLDU) in children remained stable throughout the study period.

Conclusions:

  • While pediatric research has grown, the majority of studies are not randomized controlled trials.
  • Off-label drug use in children has not decreased despite increased research activity.
  • Further investigation into improving pediatric clinical trial design and reducing OLDU is warranted.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

11.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
404
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
552
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
409
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
960
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K